Find More Contacts for Healionics
Protected Content
COO, President
Executive Operations
1 email found 1 phone number found
View contacts for Healionics to access new leads and connect with decision-makers.
View All Contacts
  • Company Type For Profit
  • Contact Email info@healionics.com
  • Phone Number (206)432-9060

Healionics has applied its expertise in synthetic biomaterials to develop a novel vascular graft (artificial blood vessel) that, unlike existing grafts, remains open to blood flow long-term without need for costly interventions. Its first commercial application will be as a more reliable means of vascular access for dialysis patients, with a

subsequent application to treat peripheral artery disease. We have great results in multiple controlled animal studies, a large patent portfolio, established production capacity, and are ready to begin human studies later this year in preparation for market launch.

Near-Term Problem / Market Opportunity: Vascular Access for Dialysis Kidney failure patients need to have their blood filtered 3 times per week via dialysis. This removes waste from the blood, which would otherwise cause them to die. However, current methods for repeatedly accessing the bloodstream for dialysis are unreliable. This problem is a huge contributor to the $50 billion per year that the U.S. spends on dialysis patients (7% of Medicare’s entire budget!). A vascular graft is often implanted under the skin (connecting an artery to a vein) to create an access site with sufficient bloodflow for dialysis -- but existing grafts tend to occlude quickly, requiring repeated expensive interventions to keep them open.

Solution: STARgraft Because our vascular graft remains open to blood flow much longer than existing grafts, it can potentially satisfy a severe unmet clinical need for ready-to-use, safe, long-term dialysis access, while substantially reducing costs, illness and death rate among dialysis patients.

Product Pipeline We have additional products in development, including an implantable port which will allow needle-free dialysis. Eliminating the use of needles would further reduce cost and illness among dialysis patients, and allow them to perform dialysis in the convenience of their own home. In addition, our platform STAR biomaterial can improve the performance of a wide range of implantable devices via its remarkable ability to prevent both infection and scar tissue. We currently have two corporate-funded development contracts to explore STAR material’s use in multiple other device applications.

Lists Featuring This Company

Washington Companies With Fewer Than 50 Employees (Top 10K)
9,341 Number of Organizations • $16.2B Total Funding Amount • 6,187 Number of Investors
West Coast Early Stage Companies
4,347 Number of Organizations • $139.1B Total Funding Amount • 32,679 Number of Investors
Western US Biotechnology Companies with Early Stage Venture Funding
519 Number of Organizations • $27.4B Total Funding Amount • 3,328 Number of Investors
Seattle Health Care Companies
1,035 Number of Organizations • $8.3B Total Funding Amount • 915 Number of Investors

Frequently Asked Questions

Where is Healionics's headquarters? Healionics is located in Seattle, Washington, United States.Who invested in Healionics? Healionics has 12 investors including Keiretsu Capital and Tom Carroux.How much funding has Healionics raised to date? Healionics has raised .When was the last funding round for Healionics? Healionics closed its last funding round on Nov 7, 2023 from a Series A round.Who are Healionics's competitors? Alternatives and possible competitors to Healionics may include Tandem Diabetes Care"Pathway Genomics", and Nano Precision Medical.